

January 10, 2017

The Department of Corporate Services BSE Limited 25th Floor, P J Towers, Dalal Street, Mumbai – 400 001

Dear Sir,

Sub.

: Statement of Investor Complaints for the quarter ended on December 31, 2016

Scrip code

533288

Please find enclosed Statement of Investor Complaints for the quarter ended on December 31, 2016, pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Request you to take the above information on your record.

Thanking You.

Yours faithfully,

For Claris Lifesciences Limited

Kirit Kanjaria

Sr. VP- Company Secretary & Compliance Officer

Encl: a/a







Statement of Investor Complaints pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Name of the Company:

Claris Lifesciences Limited

Quarter ending

December 31, 2016

Particulars	No of Grievances
Number of investor complaints pending at the beginning of the Quarter	01
Number of investor complaints received during the Quarter	00
Number of investor complaints disposed of during the Quarter	00
Number of investor complaints remaining unresolved at the end of the Quarter	01

For Claris Lifesciences Limited

Date: January 10, 2017

Place: Ahmedabad

KHKAMPANS Kirit Kanjaria

Sr. VP- Company Secretary & Compliance Officer

